#Checkmate 227 trial#
#Checkmate 227 plus#
#Checkmate 227 free#

He continued: “Oncologists considered melanoma different to other cancers – it couldn’t be treated once it had spread. “In the past, metastatic melanoma was regarded as untreatable,” commented Larkin. Each nivolumab arm was compared to ipilimumab monotherapy.

#Checkmate 227 plus#

A total of 945 patients with previously untreated stage III or IV melanoma were randomly allocated in a 1:1:1 ratio to 1) nivolumab plus ipilimumab 2) nivolumab plus placebo or 3) ipilimumab plus placebo until progression or unacceptable toxicity. The analysis is the longest Phase III follow-up for checkpoint inhibitor combination therapy. With ipilimumab monotherapy, which has been used for around 10 years, around 20% of patients are long-term survivors and the remainder live for just 6-9 months.” “10 years ago, the 5-year survival for melanoma was around 5%. “This is a major improvement on what we have seen historically,” commented James Larkin (Royal Marsden NHS Foundation Trust, London, UK). Results from the 5-year analysis of CheckMate 067 have demonstrated five-year overall survival rates of 52% for nivolumab plus ipilimumab, 44% for nivolumab, and 26% for ipilimumab. Source: One in two patients survive metastatic melanoma after 5 years with combination immunotherapy In addition, olaparib did not increase side-effects compared to placebo.” Previous studies of relapse have suggested benefits from combining anti-angiogenic agents and PARP inhibitors and today’s results appear to support this. “Patient selection was not restricted by surgical outcome or BRCA mutation status, so participants represent the general population of women with advanced ovarian cancer.

#Checkmate 227 free#

Study author Isabelle Ray-Coquard (Universite Claude Bernard, Lyon, France) commented: “This study reports the greatest hazard ratio (0.59) and longest progression free survival we have ever seen,” In this all-comers population, including women with and without a BRCA mutation, the more intensive olaparib regimen was discovered to extend progression free survival the median in the olaparib group was 22.1 months, compared with 16.6. The patients were then randomized 2:1 to receive the PARP inhibitor olaparib or a placebo in combination with bevacizumab. The study enrolled 806 participants with stage III/IV ovarian cancer who had had a partial or complete response to standard platinum-based therapy and bevacizumab.

#Checkmate 227 trial#

The PAOLA-1/ENGOT-ov25 trial is the first Phase III trial to examine the efficacy and safety of a PARP inhibitor with bevacizumab as first-line maintenance therapy. Olaparib and bevacizumab show a benefit in ovarian cancerĭata presented from the PAOLA-1/ENGOT-ov25 trial have demonstrated the benefit of a more intensive maintenance regimen, consisting of the PARP inhibitor olaparib added to bevacizumab, for ovarian cancer. To mark the first day of the ESMO Congress 2019 (27 September – 1 October, Barcelona, Spain) we have collated key news headlines for you.